



RELiZORB® (IMMOBILIZED LIPASE) CARTRIDGE is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

RELiZORB has a permanent, separately billable Medicare billing code: B4105

## Peer to Peer Preparation

1

Have patient clinical documentation readily available, including clinic notes and growth charts

2

Be prepared to discuss your rationale for medical necessity

3

Explain why RELiZORB may be right for the patient, including potential benefits and risks

## Clinical Support

- Two clinical studies covering both pediatric and adult patients for RELiZORB have been completed, which have both met their primary endpoints, both found use of RELiZORB to be safe and effective, and their results have been published in peer-reviewed journals.<sup>1,2</sup>

For more information about the clinical studies, including efficacy and safety, visit [www.relizorbhcp.com](http://www.relizorbhcp.com).

- There is no clinical safety or efficacy data supporting the use of PERT capsules in enteral feeding.<sup>3</sup> PERT capsules are indicated for oral use only and are not formulated to be crushed or added to enteral feeding systems.<sup>3</sup>
- PERTs used with enteral feeding may result in serious problems, including clogging, over-exposure to enzymes, and risks to caregivers due to crushing of pills and accidental inhalation of crushed PERTs.<sup>4</sup>

## Community Support

- In 2023, the Cystic Fibrosis (CF) Foundation published a position paper in the Journal of Cystic Fibrosis stating that using inline enzyme cartridges with immobilized lipase are safe and effective for digesting nutrients in people with CF with enteral tube feeds.<sup>5</sup>
- In 2020, for non-CF patients, a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) deemed it reasonable and prudent to extrapolate the RELiZORB data for nutritional management of patients with exocrine pancreatic insufficiency (EPI) caused by rarer diseases.<sup>6</sup>
- The NASPGHAN Pancreas Committee recommends the use of RELiZORB in children with chronic pancreatitis who require enteral feedings.<sup>6</sup>

1. Freedman S, Orenstein D, Black P, et al. Increased fat absorption from enteral formula through an in-line digestive cartridge in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2017;65(1):97-101.  
2. Stevens J, Wyatt C, Brown P, Patel D, Grujic D, Freedman SD. Absorption and Safety with Sustained Use of RELiZORB Evaluation (ASSURE) study in patients with cystic fibrosis receiving enteral feeding. J Pediatr Gastroenterol Nutr. 2018;Oct;67(4):527-532.  
3. Berry, AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract. 2014;29(3):312-321.  
4. Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin Pract. 2011;26(3):349-351.  
5. Leonard A, Bailey J, Bruce A, et al. Nutritional considerations for a new era: A CF foundation position paper. Journal of Cystic Fibrosis. 2023;22(5):788-795.  
6. Freeman AJ, Maqbool A, Bellin MD, et al. Medical Management of Chronic Pancreatitis in Children: A Position Paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Pancreas Committee. Journal of Pediatric Gastroenterology and Nutrition. 2021 Feb;72(2):324-340.

**Disclaimer:** The above information is intended to be used only by healthcare professionals and includes and provides information that may be helpful in responding to payer questions during a peer-to-peer engagement. All patient reimbursement discussions and engagements should be based on the provider's evaluation of the patient and their condition.

**Safety:** RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELiZORB. Please see Instructions for Use for full safety information at [www.relizorbhcp.com](http://www.relizorbhcp.com).